BioTuesdays

Category - Markets

Aerie Pharmaceuticals Logo

Stifel ups Aerie Pharma price target to $50

Stifel raised it price target for Aerie Pharmaceuticals (NASDAQ:AERI) to $50 from $40 after the company’s Roclatan eye drop hit all its endpoints with clinically meaningful results in a Phase 3 trial. The stock closed...

Vitae Pharmaceuticals

Stifel downgrades Vitae Pharma to hold

Stifel downgraded Vitae Pharmaceuticals (NASDAQ:VTAE) to “hold” from “buy” with a new price target of $21 after the company accepted a merger agreement from Allergan (NYSE:AGN) valued at $639-million or $21 a share. In...

ViewRay Logo

BTIG starts ViewRay at buy

BTIG Research launched coverage of ViewRay (NASDAQ:VRAY) with a “buy” rating and $6 price target. The stock closed at $3.58 on Tuesday. MRIdian is the first commercial MRI guided radiation therapy treatment system...

novadaq

Scotiabank starts Novadaq at sector outperform

Scotiabank initiated coverage of Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) with a “sector outperform” rating and a one-year price target of $18.  The stock closed at $11.43 on Tuesday. Analyst Alan Ridgeway writes...

Mirna Therapeutics

Wainwright starts Mirna Therapeutics at buy

H.C. Wainwright initiated coverage of Mirna Therapeutics (NASDAQ:MIRN) with a ‘buy” rating and $6 price target, saying the company’s promising microRNA technology “could be a gift to long-term investors.” The stock was...

Cogentix Medical

Roth upgrades Cogentix Medical to buy

Roth Capital Partners upgraded Cogentix Medical (NASDQQ:CGNT) to “buy” from “neutral” and raised its price target to $2.20 from $1.25 after the company announced proposed equity financing and debt conversion...

Nabriva Therapeutics Logo

Wainwright starts Nabriva Therapeutics at buy

H.C. Wainwright initiated coverage of Nabriva Therapeutics (NASDAQ:NBRV) with a “buy” rating and $16 price target. The stock closed at $7.92 on Wednesday. Originally spun-off from Sandoz, Austria-based Nabriva has in...

Protagonist Therapeutics

Leerink starts Protagonist Therapeutics at outperform

Leerink Partners launched coverage of Protagonist Therapeutics (NASDAQ:PTGX) with an “outperform” rating and $17 price target in 12 months. The stock closed at $12.08 on Friday. Protagonist is aiming to become the...

Endologix

Leerink starts Endologix at market perform

Leerink Partners initiated coverage of Endologix (NASDAQ:ELGX) with a “market perform” rating and $13 price target. The stock closed at $12.22 on Friday. Endologix is the largest abdominal aortic aneurysm (AAA) pure...

Atossa Genetics

Atossa Genetics prices common stock offering

Atossa Genetics (NASDAQ:ATOS) has priced a public offering of 1,150,000 common shares at a price of $2.50 a share for gross proceeds of about $2,875,000. Atossa Genetics also granted underwriters a 45-day option to...